1-4 of 4
Thomas Staudinger
Close
Sort by
Journal Articles

Emicizumab for the Treatment of Acquired Hemophilia_A: Lessons Learned from 4 Very Different Cases

Paul Knoebl, MD, Wolfgang R. Sperr, Peter Schellongowski, MD, Thomas Staudinger, MD, Petra Jilma-Stohlawetz, MD, Peter Quehenberger, MD, Silvia Koder, Ing, Cihan Ay, MD, Karoline V. Gleixner, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2476.
https://doi.org/10.1182/blood-2018-99-116973
Published: 2018
Journal Articles

Incidence of Intensive Care Unit Admission, Outcome, and Post Intensive Care Survival in Patients with Acute Lymphocytic Leukemia or Burkitt Lymphoma

Peter Schellongowski, MD, Philipp Wohlfarth, MD, Kundi Michael, MD, Alexander Hauswirth, MD, Andja Bojic, MD, Werner Rabitsch, MD, Ulrich Jäger, MD, Peter Valent, MD, Thomas Staudinger, MD, Wolfgang R. Sperr
Journal: Blood
Blood (2014) 124 (21): 2633.
https://doi.org/10.1182/blood.V124.21.2633.2633
Published: 2014
Journal Articles

Treatment Of Infection-Associated Purpura Fulminans With Protein C Zymogen Is Associated With a High Survival Rate

Paul Knoebl, MD, Peter Schellongowski, MD, Thomas Staudinger, MD, Wolfgang R. Sperr, MD, Christian Scheibenpflug, MD
Journal: Blood
Blood (2013) 122 (21): 3606.
https://doi.org/10.1182/blood.V122.21.3606.3606
Published: 2013
Journal Articles

Prognostic Factors Predicting Survival in De Novo AML Patients Requiring Intensive Care.

Peter Schellongowski, MD, Thomas Staudinger, Klaus Laczika, Gottfried Locker, Andja Bojic, MD, Ulrich Jaeger, Peter Valent, Wolfgang R. Sperr
Journal: Blood
Blood (2007) 110 (11): 2860.
https://doi.org/10.1182/blood.V110.11.2860.2860
Published: 2007